Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Piramal Close To Buying Local Critical Care Brands With An Eye On Global Markets

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Indian drug maker Piramal Healthcare's ambition to grow into a world player in hospital and critical care products is set to cross another milestone with the likely acquisition of a few brands in the anesthesia segment from an unlisted Indian pharmaceutical company

You may also be interested in...



Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy

NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21

Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy

NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21

Abbott's Piramal Acquisition Is $3.72 Billion Push In Emerging Markets With Established Products

NEW DELHI - Abbott is all set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare, ending months of speculation on which multinational would secure India's fourth-largest pharma compan

Related Content

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel